AbCellera Biologics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbCellera Biologics Inc.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Alloy raises $75m in venture funding to further its mission of open-source antibody technology discovery. It also spins out portfolio companies, like ophthalmic-focused Broadwing.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
- Digital Health
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
Drug Discovery Tools